RPRX Royalty Pharma Earnings and EPS analysis

EPS in 2025 (TTM): $2.31

Last Report Period Date: Jun 30, 2025

As of August 2025, according to Royalty Pharma's latest financial report, the company's current EPS (TTM) is $2.31. In 2024, the company recorded an earnings per share (EPS) of $1.92, which represents a decrease compared to its EPS of $2.54 in 2023. Royalty Pharma's earnings per share for the quarterly report ending on Jun 30, 2025 was $0.07.

The annual EPS in 2024 was $1.92, a decrease of 24.4% from $2.54 in 2023. For the quarter ending Jun 30, 2025, the EPS was $0.07, showing a 69.6% decrease from the same quarter last year. The trailing twelve months (TTM) EPS as of June 2025 is $2.31. In 2023, the annual EPS was $2.54, showing an increase of 2,440% from 2022.

Royalty Pharma has recorded a decrease in EPS of 69.6% over the last 12 months (YoY, quarterly). Looking at a longer timeframe, the company recorded an average EPS growth rate of 8.8% per year over the past 3 years.